Gabelli Funds LLC Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Gabelli Funds LLC lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 100.0% during the 4th quarter, Holdings Channel reports. The firm owned 550 shares of the biopharmaceutical company’s stock after selling 1,999,450 shares during the quarter. Gabelli Funds LLC’s holdings in Alnylam Pharmaceuticals were worth $219,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ALNY. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth $243,000. Geneos Wealth Management Inc. lifted its stake in Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth $241,000. Daiwa Securities Group Inc. lifted its stake in Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after purchasing an additional 703 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $297.45 on Monday. The firm’s 50-day moving average price is $311.16 and its 200-day moving average price is $358.96. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market capitalization of $39.71 billion, a price-to-earnings ratio of 81.27 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12-month low of $284.19 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s revenue was up 96.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.44) EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Insider Activity

In other news, EVP Tolga Tanguler sold 1,598 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $523,584.70. Following the sale, the executive vice president directly owned 36,606 shares in the company, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,652 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $319.73, for a total transaction of $528,193.96. Following the sale, the executive vice president owned 21,860 shares in the company, valued at $6,989,297.80. This represents a 7.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 21,255 shares of company stock worth $6,930,337. 0.86% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on ALNY. Citigroup began coverage on shares of Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price target on the stock. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Barclays assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.